Condition: Graves' Disease · Sponsor: Yarrow Bioscience, Inc.
This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body. The study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period. Participants will receive YB-101 or Placebo subcutaneously. Participants who participate in Part 1 can not participate in Part 2. Participants will complete 34-39 in-clinic visits in Part 1 or Part 2 over an approximate 40 week period.
This description comes directly from the study's public registry record.
Victoria Lacasse, MD · 469-278-6161 · VL@YarrowBioscience.com
Always discuss trial participation with your own doctor first.
| Site 112 | Gilbert, Arizona, United States | Recruiting |
| Site 130 | Phoenix, Arizona, United States | Not Yet Recruiting |
| Site 121 | La Mesa, California, United States | Not Yet Recruiting |
| Site 103 | Sacramento, California, United States | Not Yet Recruiting |
| Site 111 | San Francisco, California, United States | Not Yet Recruiting |
| Site 105 | Torrance, California, United States | Not Yet Recruiting |
| Site 109 | Miami Lakes, Florida, United States | Recruiting |
| Site 115 | Palm Harbor, Florida, United States | Not Yet Recruiting |
| Site 123 | Sarasota, Florida, United States | Not Yet Recruiting |
| Site 118 | Macon, Georgia, United States | Recruiting |
| Site 122 | Bowling Green, Kentucky, United States | Not Yet Recruiting |
| Site 126 | Flint, Michigan, United States | Not Yet Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07682896